» Articles » PMID: 21160069

Cytokine Signature Profiles in Acquired Aplastic Anemia and Myelodysplastic Syndromes

Overview
Journal Haematologica
Specialty Hematology
Date 2010 Dec 17
PMID 21160069
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Although aplastic anemia and myelodysplasia have been extensively investigated, little is known about their circulating cytokine patterns. We compared plasma soluble cytokines in 33 aplastic anemia, 57 myelodysplasia patients, and 48 healthy controls. High levels of thrombopoietin and granulocyte colony-stimulating factor, with low levels of CD40 ligand, chemokine (C-X-C motif) ligand 5, chemokine (C-C motif) ligand 5, chemokine (C-X-C motif) ligand 11, epidermal growth factor, vascular endothelial growth factor, and chemokine (C-C motif) ligand 11 were a signature profile for aplastic anemia. High levels of tumor necrosis factor-α, interleukin-6, chemokine (C-C motif) ligand 3, interleukin-1 receptor antagonist, and hepatocyte growth factor were a cytokine signature for myelodysplasia. Despite similar clinical presentations, distinct cytokine profiles were observed between aplastic anemia and hypocellular myelodysplasia. Future studies focusing on cytokines that better discriminate these two entities such as thrombopoietin and chemokine (C-C motif) ligand 3 may be useful tools in clinical practice.

Citing Articles

CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview.

Abdalhadi H, Chatham W, Alduraibi F Int J Mol Sci. 2024; 25(19).

PMID: 39408836 PMC: 11476835. DOI: 10.3390/ijms251910511.


Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention.

Li J, Chen H, Xu C, Hu M, Li J, Chang W Front Immunol. 2024; 15:1422591.

PMID: 39253080 PMC: 11381299. DOI: 10.3389/fimmu.2024.1422591.


Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.

Tentori C, Zhao L, Tinterri B, Strange K, Zoldan K, Dimopoulos K Hemasphere. 2024; 8(5):e64.

PMID: 38756352 PMC: 11096644. DOI: 10.1002/hem3.64.


Progress in medical therapy in aplastic anemia: why it took so long?.

Scheinberg P Int J Hematol. 2024; 119(3):248-254.

PMID: 38403842 DOI: 10.1007/s12185-024-03713-3.


All Roads Lead to Interferon-γ: From Known to Untraveled Pathways in Acquired Aplastic Anemia.

Serio B, Giudice V, Selleri C Medicina (Kaunas). 2023; 59(12).

PMID: 38138273 PMC: 10744863. DOI: 10.3390/medicina59122170.


References
1.
Linenberger M, Jacobson F, Bennett L, Broudy V, Martin F, Abkowitz J . Stem cell factor production by human marrow stromal fibroblasts. Exp Hematol. 1995; 23(10):1104-14. View

2.
Kojima S, Matsuyama T, Kodera Y, Nishihira H, Ueda K, Shimbo T . Measurement of endogenous plasma granulocyte colony-stimulating factor in patients with acquired aplastic anemia by a sensitive chemiluminescent immunoassay. Blood. 1996; 87(4):1303-8. View

3.
Marsh J, Gibson F, Prue R, Bowen A, Dunn V, Hornkohl A . Serum thrombopoietin levels in patients with aplastic anaemia. Br J Haematol. 1996; 95(4):605-10. DOI: 10.1046/j.1365-2141.1996.d01-1966.x. View

4.
Vardiman J, Lee Harris N, Brunning R . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100(7):2292-302. DOI: 10.1182/blood-2002-04-1199. View

5.
Young N, Calado R, Scheinberg P . Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006; 108(8):2509-19. PMC: 1895575. DOI: 10.1182/blood-2006-03-010777. View